The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Orally Disintegrating Tablet Market By 2030?
The orally disintegrating tablet market has seen substantial growth in recent years. It is projected to expand from $16.2 billion in 2025 to $17.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. Historically, this growth can be linked to factors like limited awareness of orally disintegrating tablets, the prevalence of conventional tablets, insufficient targeting of pediatric and geriatric patients, dependence on hospital pharmacy channels, and the slow integration of specialty drug formulations.
The orally disintegrating tablet market is anticipated to experience substantial expansion over the coming years. It is projected to reach $24.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period can be attributed to several factors, including advancements in ODT formulation technology, a growing patient preference for convenient and compliant medication options, the expansion of both online and retail pharmacy networks, the increasing incidence of central nervous system (CNS) and gastrointestinal disorders, and augmented research and development efforts in anti-psychotics and anti-epileptics. Key developments expected during this period involve a rising demand for easily ingestible and patient-friendly dosage forms, increased targeting of pediatric and geriatric patient populations, the broadening of hospital and retail pharmacy distribution channels, a heightened focus on therapies with rapid onset, and the increasing incorporation of specialty drug classes into ODT formulations.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp
What Market Drivers Are Helping Shape The Orally Disintegrating Tablet Market Expansion?
The orally disintegrating tablet market is anticipated to expand due to the rising occurrence of neurological disorders. These conditions are defined as medical issues impacting the nervous system, encompassing the brain and peripheral nerves, thereby interfering with its normal operations. A primary reason for the increased prevalence of neurological disorders is extended lifespans, given that conditions like Alzheimer’s and Parkinson’s occur more frequently in older individuals, resulting in a general rise in diagnoses. Orally disintegrating tablets offer assistance in managing neurological disorders by facilitating quicker and simpler drug delivery, especially for individuals facing swallowing difficulties (dysphagia) or cognitive issues. They also boost patient compliance, guarantee appropriate dosing, and heighten therapeutic efficacy. As an illustration, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts suggesting this number will climb to 13.8 million by 2060. Consequently, the growing frequency of neurological disorders is a significant factor propelling the expansion of the orally disintegrating tablet market.
What Segment Categories Are Evaluated In The Orally Disintegrating Tablet Market Study?
The orally disintegrating tablet market covered in this report is segmented –
1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes
What Trends Are Affecting The Orally Disintegrating Tablet Market Dynamics?
Companies operating within the orally disintegrating tablet market are prioritizing advancements in drug formulation, specifically patient-centric drug delivery systems, to enhance treatment adherence and improve patient outcomes. A patient-centric drug delivery system refers to a method of designing and administering medicines to make them easier and more comfortable for patients to take, thereby improving their treatment experience and adherence. For instance, in May 2025, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product provides several unique features, making it a significant addition to the management of treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) available in the country, it presents a patient-friendly option that disintegrates quickly in the mouth without water, assisting those with difficulty swallowing or adherence challenges. The product is available in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling flexible and precise dose titration based on individual patient needs. By utilizing clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation supports alignment with established treatment protocols.
Which Companies Form The Competitive Landscape Of The Orally Disintegrating Tablet Market?
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.
Access The Complete Orally Disintegrating Tablet Market Report:
https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report
Which Area Represents The Largest Portion Of The Orally Disintegrating Tablet Market?
North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Orally Disintegrating Tablet Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp
Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company
Tablets Market Report 2026
https://www.thebusinessresearchcompany.com/report/tablets-global-market-report
Effervescent Tablet Market Report 2026
https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model